Aquestive Therapeutics Shares Decline Due to Decreased Revenue and Regulatory Setbacks

Aquestive Therapeutics shares are trading lower after the company reported a 28% decrease in Q1 2025 revenue, primarily due to regulatory setbacks affecting Libervant and increased expenses.